

We Claim:

1. A system for treating an individual experiencing a chronic physiologic condition that is characterized by abnormal levels of cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, the system comprising a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from blood by selective adsorption, and means for circulating the blood of the individual through the material.

2. A system according to claim 1 further including means for administering an agent to the individual selected to treat the chronic physiologic condition.

3. A system according to claim 1 wherein the means for circulating includes an intravenous catheter.

4. A system according to claim 1 wherein the means for circulating includes an indwelling catheter.

5. A system according to claim 1 wherein the means for circulating includes tubing having a wall impregnated with the material.

6. A system according to claim 1 wherein the means for circulating includes an in-line housing, and wherein the material is contained within the housing.

7. A system according to claim 1 wherein the means for circulating includes an in-line exchangeable housing, and wherein the material is contained within the housing.

8. A system according to claim 1 wherein the means for circulating and the

Sub
a!
10036759-122101
TOTAL 5529007

material are sized to be carried with the individual during ambulation.

9. A system according to claim 1
wherein the material is characterized by a Biocompatibility Index of not greater than 14.

10. A system according to claim 9
wherein the Biocompatibility Index is not greater than 7.

11. A system according to claim 1
wherein the material comprises a polymeric material.

12. A system according to claim 11
wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α -methylstyrene, divinylbenzene, diisopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

13. A system according to claim 11
wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.

14. A system according to claim 11
wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-vinylcaprolactame and N-acrylamide.

15. A system according to claim 11
wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of

Sub
a!
10036759 122101
TOTAL 65221

5

5

5

5

porogens with properties close to those of θ -solvents.

16. A system for treating an individual experiencing a chronic physiologic condition comprising means for diagnosing that the chronic physiologic condition is accompanied by abnormal levels of cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood,

a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from blood by selective adsorption, and

means for circulating the blood of the individual through the material to remove cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators.

17. A system according to claim 16 further including means for administering an agent to the individual selected to treat the chronic physiologic condition.

18. A system according to claim 16 wherein the means for circulating includes an intravenous catheter.

19. A system according to claim 16 wherein the means for circulating includes an indwelling catheter.

20. A system according to claim 16 wherein the means for circulating includes tubing having a wall impregnated with the material.

21. A system according to claim 16 wherein the means for circulating includes an in-line housing, and wherein the material is contained within the housing.

22. A system according to claim 16 wherein the means for circulating includes an in-line exchangeable housing, and

Sub
A1

10036759-133101

5 wherein the material is contained within the housing.

23. A system according to claim 16 wherein the means for circulating and the material are sized to be carried with the individual during ambulation.

24. A system according to claim 16 wherein the material is characterized by a Biocompatibility Index of not greater than 14.

25. A system according to claim 24 wherein the Biocompatibility Index is not greater than 7.

26. A system according to claim 16 wherein the material comprises a polymeric material.

5 27. A system according to claim 26 wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α -methylstyrene, divinylbenzene, diisopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

5 28. A system according to claim 26 wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.

5 29. A system according to claim 26 wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-vinylcaprolactame and N-acrylamide.

30. A system according to claim 26

10036759-122101

wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of θ -solvents.

31. A method for treating an individual experiencing a chronic physiologic condition comprising the steps of

diagnosing that the chronic physiologic condition is accompanied by abnormal levels of cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, and

circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

32. A method according to claim 31 further including administering an agent to the individual selected to treat the chronic physiologic condition.

33. A method for treating an individual experiencing rheumatoid arthritis comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

34. A method according to claim 33 further including administering an agent to the individual selected to treat rheumatoid arthritis.

35. A method for treating an individual experiencing emphysema comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

10036759-122101
TOTAL 65295001

36. A method according to claim 35
further including administering an agent to the
individual selected to treat emphysema.

5 37. A method for treating an individual
experiencing asthma comprising the step of circulating the
blood of the individual through a material that removes
cytokines or other species of pro-inflammatory or anti-
inflammatory stimulators or mediators by selective
adsorption.

38. A method according to claim 37
further including administering an agent to the
individual selected to treat asthma.

5 39. A method for treating an individual
experiencing pulmonary failure comprising the step of
circulating the blood of the individual through a material
that removes cytokines or other species of pro-inflammatory
or anti-inflammatory stimulators or mediators by selective
adsorption.

40. A method according to claim 39
further including administering an agent to the
individual selected to treat pulmonary failure.

5 41. A method for treating an individual
experiencing ARDS comprising the step of circulating the
blood of the individual through a material that removes
cytokines or other species of pro-inflammatory or anti-
inflammatory stimulators or mediators by selective
adsorption.

42. A method according to claim 41
further including administering an agent to the
individual selected to treat ARDS.

5 43. A method for treating an individual
experiencing viral hepatitis comprising the step of
circulating the blood of the individual through a material
that removes cytokines or other species of pro-inflammatory
or anti-inflammatory stimulators or mediators by selective

10036759 122101

adsorption.

44. A method according to claim 43 further including administering an agent to the individual selected to treat viral hepatitis.

5 45. A method for treating an individual experiencing myocardial ischemia comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

46. A method according to claim 45 further including administering an agent to the individual selected to treat myocardial ischemia.

5 47. A method for treating an individual experiencing autoimmune disease comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

48. A method according to claim 47 further including administering an agent to the individual selected to treat autoimmune disease.

5 49. A method for treating an individual experiencing AIDS comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

50. A method according to claim 49 further including administering an agent to the individual selected to treat AIDS.

51. A method for treating an individual exposed to a biological or chemical agent comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory

10036759-12101
TOT22T 6529E00T

5 or anti-inflammatory stimulators or mediators by selective adsorption.

52. A method according to claim 51 further including administering an agent to the individual selected to treat the exposure.

53. ✓ A method for treating an individual exposed to anthrax comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

54. A method according to claim 53 further including administering an agent to the individual selected to treat anthrax.

55. A method according to claim 31 or 33 or 35 or 37 or 39 or 41 or 43 or 45 or 47 or 49 or 51 or 53 wherein the material comprises a polymeric material.

56. A method according to claim 55 wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α -methylstyrene, divinylbenzene, diisopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

57. A method according to claim 55 wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.

58. A method according to claim 55 wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine,

10036759-12101
TOTAL 65295007

N-vinylcaprolactame and N-acrylamide.

5

59. A method according to claim 55 wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of θ -solvents.

60. A method according to claim 31 or 33 or 35 or 37 or 39 or 41 or 43 or 45 or 47 or 49 or 51 or 53 wherein the material is characterized by a Biocompatibility Index of not greater than 14.

61. A method according to claim 60 wherein the Biocompatibility Index is not greater than 7.

62. A system for treating an individual experiencing trauma before onset of septic shock comprising a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from blood by selective adsorption, and means for circulating the blood of the individual through the material.

63. A system according to claim 62 further including means for administering an agent to the individual selected to treat trauma.

64. A system according to claim 62 wherein the means for circulating includes an intravenous catheter.

65. A system according to claim 62 wherein the means for circulating includes an indwelling catheter.

66. A system according to claim 62 wherein the means for circulating includes tubing having a wall impregnated with the material.

67. A system according to claim 62 wherein the means for circulating includes an

10036759-122401

Sub
a1

in-line housing, and

wherein the material is contained within the housing.

5

68. A system according to claim 62

wherein the means for circulating includes an in-line exchangeable housing, and

wherein the material is contained within the housing.

69. A system according to claim 68

wherein the means for circulating and the material are sized to be carried with the individual during ambulation.

70. A system according to claim 62

wherein the material is characterized by a Biocompatibility Index of not greater than 14.

71. A system according to claim 70

wherein the Biocompatibility Index is not greater than 7.

72. A system according to claim 62

wherein the material comprises a polymeric material.

73. A system according to claim 72

wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α -methylstyrene, divinylbenzene, diisopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

5

74. A system according to claim 72

wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.

5

75. A system according to claim 72

wherein the polymeric material comprises

Sub
5
10036759-122101
FOI 2017-05295007

Sub⁵
a¹

particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-vinylcaprolactame and N-acrylamide.

5 76. A system according to claim 72 wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of θ -solvents.

5 77. A method for treating an individual experiencing trauma before the onset of septic shock comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

78. A method according to claim 77 further including administering an agent to the individual selected to treat trauma.

5 79. A method for treating an individual undergoing or about to undergo surgery comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

5 80. A method for treating a burn victim comprising the step of circulating the blood of the burn victim through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

81. A method for treating an individual experiencing a cardiac condition comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory

10036759-122101

5 or anti-inflammatory stimulators or mediators by selective adsorption.

82. A method for treating an individual selected for or having received an organ transplant comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

83. A method for treating an individual selected for or having received reconstructive surgery comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

84. A method for treating an individual experiencing ischemia-reperfusion injury comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

85. A method for treating an individual experiencing "the crush syndrome" comprising the step of circulating the blood of the individual through a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators by selective adsorption.

86. A method according to claim 77 or 79 or 80 or 81 or 82 or 83 or 84 or 85 wherein the material comprises a polymeric material.

87. A method according to claim 86 wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene, α -methylstyrene, divinylbenzene, di

10036759-132101

isopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

5 88. A method according to claim 86
wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.

5 89. A method according to claim 86
wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-vinylcaprolactame and N-acrylamide.

5 90. A method according to claim 86
wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of θ -solvents.

91. A method according to claim 77 or 79 or 80 or 81 or 82 or 83 or 84 or 85

wherein the material is characterized by a Biocompatibility Index of not greater than 14.

92. A method according to claim 91
wherein the Biocompatibility Index is not greater than 7.

10036759-122101